Access is decided long before launch
The evidence that determines access is largely fixed by the time a product reaches HTA. Comparators, endpoints, follow-up and subgroups are set in the trial programme years earlier. Market access strategy therefore has to start early, connect clinical development with the questions payers will ask, and keep the value story consistent from the first advisory board to the final pricing agreement.
What we deliver
- Market access strategy and integrated evidence planning
- Payer landscaping, stakeholder mapping and value message testing
- Global value dossiers, value stories and payer question-and-answer guides
- HTA submissions in the UK, Ireland and the EU
- Pricing and reimbursement strategy, launch sequencing and international reference pricing and MFN analysis
- Managed access and commercial arrangement design
- Adoption and uptake planning, including local business cases
Market access in Ireland
In Ireland, the HSE Corporate Pharmaceutical Unit commissions the NCPE, every medicine starts with a rapid review, and the CPU leads the commercial negotiation. Market access consultancy in Ireland therefore means planning the rapid review, the possible full HTA and the commercial offer as one piece of work, with budget impact in view from day one. See NCPE submissions and HSE reimbursement.
Market access in the UK
In the UK, access runs through NICE in England, the SMC in Scotland and AWMSG in Wales, each with its own process and timelines. NICE has used a range of £25,000 to £35,000 per QALY since April 2026, and managed access can bridge evidence gaps for promising medicines. See NICE, SMC and AWMSG submissions, SMC submissions and managed access.
Market access across Europe
Across the EU, the joint clinical assessment now feeds national decisions on value and price in each Member State. Our HTA requirements comparison sets the main systems side by side, with detailed pages for Germany, France, the Netherlands, Belgium, the Nordics and Romania. US pricing interacts through MFN: see our analysis of MFN and European launches.
Why Evidaxia
We bring HTA assessor experience, health economic depth and senior strategic judgement to the same table, so access strategy is grounded in what the evidence can actually support.